Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Pfizer (PFE) Tops Q1 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance
May 5, 2026 6:46 AM EDTPfizer (NYSE: PFE) reported Q1 EPS of $0.75, $0.03 better than the analyst estimate of $0.72. Revenue for the quarter came in at $14.5 billion versus the consensus estimate of $13.84 billion.
GUIDANCE:
Pfizer sees FY2026 EPS of $2.80-$3.00, versus the consensus of $2.96.
For earnings history and earnings-related data on Pfizer (PFE) click here.
... More